ASX - By Stock
|
MSB |
Re:
Why has Novartis taken down the MSB media release from their website?
|
|
Yor
|
28 |
11K |
6 |
13/08/21 |
13/08/21 |
ASX - By Stock
|
28
|
11K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Yor
|
17K |
6.7M |
14 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
17K
|
6.7M
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Yor
|
17K |
6.7M |
45 |
08/08/21 |
08/08/21 |
ASX - By Stock
|
17K
|
6.7M
|
45
|
|
ASX - By Stock
|
MSB |
Re:
Novartis countdown
|
|
Yor
|
373 |
112K |
19 |
17/06/21 |
17/06/21 |
ASX - By Stock
|
373
|
112K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 USA Daily Numbers
|
|
Yor
|
675 |
193K |
1 |
06/04/21 |
06/04/21 |
ASX - By Stock
|
675
|
193K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 USA Daily Numbers
|
|
Yor
|
675 |
193K |
8 |
05/04/21 |
05/04/21 |
ASX - By Stock
|
675
|
193K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 USA Daily Numbers
|
|
Yor
|
675 |
193K |
4 |
18/03/21 |
18/03/21 |
ASX - By Stock
|
675
|
193K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Update on COVID-19 ARDS Trial
|
|
Yor
|
1.0K |
517K |
6 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
1.0K
|
517K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Yor
|
1.0K |
418K |
54 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
418K
|
54
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 Chronic Heart Failure Results
|
|
Yor
|
1.0K |
418K |
8 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
1.0K
|
418K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Yor
|
13K |
5.0M |
41 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
41
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Yor
|
13K |
5.0M |
9 |
15/12/20 |
15/12/20 |
ASX - By Stock
|
13K
|
5.0M
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment
|
|
Yor
|
272 |
109K |
6 |
08/12/20 |
08/12/20 |
ASX - By Stock
|
272
|
109K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment
|
|
Yor
|
272 |
109K |
16 |
04/12/20 |
04/12/20 |
ASX - By Stock
|
272
|
109K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Yor
|
811 |
334K |
68 |
28/11/20 |
28/11/20 |
ASX - By Stock
|
811
|
334K
|
68
|
|
ASX - By Stock
|
MSB |
Re:
AGM Discussion
|
|
Yor
|
254 |
100K |
2 |
24/11/20 |
24/11/20 |
ASX - By Stock
|
254
|
100K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Yor
|
392 |
158K |
4 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
392
|
158K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Yor
|
392 |
158K |
9 |
16/11/20 |
16/11/20 |
ASX - By Stock
|
392
|
158K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Yor
|
392 |
158K |
15 |
14/11/20 |
14/11/20 |
ASX - By Stock
|
392
|
158K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Overwhelming efficacy - the stats required
|
|
Yor
|
576 |
234K |
16 |
25/10/20 |
25/10/20 |
ASX - By Stock
|
576
|
234K
|
16
|
|
ASX - By Stock
|
MSB |
Re:
MSB to dispute FDA finding in Type A meeting
|
|
Yor
|
1.0K |
502K |
2 |
11/10/20 |
11/10/20 |
ASX - By Stock
|
1.0K
|
502K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
IRENE KRISTAL, I, Plaintiff, v. MESOBLAST LIMITED, SILVIU ITESCU, and JOSH MUNTNER, Defendants.
|
|
Yor
|
223 |
98K |
6 |
11/10/20 |
11/10/20 |
ASX - By Stock
|
223
|
98K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MESO action tonight
|
|
Yor
|
3.1K |
1.4M |
2 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
3.1K
|
1.4M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
FDA approval chances and time frame
|
|
Yor
|
18 |
8.8K |
3 |
15/09/20 |
15/09/20 |
ASX - By Stock
|
18
|
8.8K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Hypothetical situation of take over by a big pharma company
|
|
Yor
|
19 |
8.1K |
15 |
15/09/20 |
15/09/20 |
ASX - By Stock
|
19
|
8.1K
|
15
|
|
ASX - By Stock
|
MSB Biotech |
Re:
New video discussion with Mesoblast CEO
|
|
Yor
|
122 |
63K |
10 |
11/09/20 |
11/09/20 |
ASX - By Stock
|
122
|
63K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
Yor
|
518 |
265K |
5 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
518
|
265K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Yor
|
203 |
89K |
7 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
203
|
89K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
A thank you
|
|
Yor
|
52 |
25K |
2 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
52
|
25K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
A thank you
|
|
Yor
|
52 |
25K |
44 |
07/08/20 |
07/08/20 |
ASX - By Stock
|
52
|
25K
|
44
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Yor
|
5.4K |
2.7M |
4 |
04/08/20 |
04/08/20 |
ASX - By Stock
|
5.4K
|
2.7M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: COVID-19/GVHD Update, Quarterly Report and Appendix 4C
|
|
Yor
|
248 |
94K |
25 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
248
|
94K
|
25
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
48 |
14/07/20 |
14/07/20 |
ASX - By Stock
|
23K
|
13M
|
48
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Yor
|
17K |
6.7M |
0 |
13/07/20 |
13/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Yor
|
17K |
6.7M |
51 |
11/07/20 |
11/07/20 |
ASX - By Stock
|
17K
|
6.7M
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Yor
|
1.0K |
492K |
30 |
29/06/20 |
29/06/20 |
ASX - By Stock
|
1.0K
|
492K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Yor
|
17K |
6.7M |
2 |
29/06/20 |
29/06/20 |
ASX - By Stock
|
17K
|
6.7M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Yor
|
1.0K |
492K |
8 |
26/06/20 |
26/06/20 |
ASX - By Stock
|
1.0K
|
492K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
FAUCI Promotes Remdesivir live on CNN
|
|
Yor
|
33 |
16K |
13 |
24/06/20 |
24/06/20 |
ASX - By Stock
|
33
|
16K
|
13
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
27 |
22/06/20 |
22/06/20 |
ASX - By Stock
|
23K
|
13M
|
27
|
|
ASX - By Stock
|
MSB |
Re:
selling is riskier than holding
|
|
Yor
|
10 |
3.5K |
3 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
10
|
3.5K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
selling is riskier than holding
|
|
Yor
|
10 |
3.5K |
7 |
15/06/20 |
15/06/20 |
ASX - By Stock
|
10
|
3.5K
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
Yor
|
23K |
13M |
2 |
03/06/20 |
03/06/20 |
ASX - By Stock
|
23K
|
13M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
ecoool2 threads back
|
|
Yor
|
12 |
7.6K |
11 |
03/06/20 |
03/06/20 |
ASX - By Stock
|
12
|
7.6K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
MESOBLAST - GVHD - A BIRD IN THE HAND
|
|
Yor
|
53 |
37K |
9 |
01/06/20 |
01/06/20 |
ASX - By Stock
|
53
|
37K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Yor
|
1.0K |
492K |
15 |
27/05/20 |
27/05/20 |
ASX - By Stock
|
1.0K
|
492K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
Yor
|
518 |
265K |
6 |
25/05/20 |
25/05/20 |
ASX - By Stock
|
518
|
265K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
COVID-19 ARDS and ARDS Share Price Scenarios
|
|
Yor
|
518 |
265K |
21 |
24/05/20 |
24/05/20 |
ASX - By Stock
|
518
|
265K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Analysis of the EAP
|
|
Yor
|
1.0K |
492K |
35 |
19/05/20 |
19/05/20 |
ASX - By Stock
|
1.0K
|
492K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Pick the Closing Price after FDA approval on that day
|
|
Yor
|
449 |
189K |
0 |
19/05/20 |
19/05/20 |
ASX - By Stock
|
449
|
189K
|
0
|
|